Seres Therapeutics Appoints Interim CEO to Steer Strategic Focus

Seres Therapeutics names board member Richard Kender as interim CEO to ensure operational continuity and focus on key clinical programs, including SER-155 for infection prevention.

Seres Therapeutics is reinforcing its leadership team to maintain momentum during a period of organizational change. The biotechnology firm has named board member Richard Kender as its interim Chief Executive Officer. This move is designed to ensure operational continuity and secure key clinical objectives as the company streamlines its internal structure. Central to this strategy is the advancement of a leading therapeutic candidate for infection prevention.

Strategic Priorities Under New Leadership

Richard Kender, who has served on the Seres Therapeutics board since 2014, is now tasked with guiding the company’s day-to-day operations without disruption. He will be supported by the existing management team to preserve stability. Thomas DesRosier continues in his role as Chief Legal Officer, and Marella Thorell remains the Chief Financial Officer. This continuity in the executive suite is intended to keep the company’s research and development pipeline progressing smoothly.

The company’s primary focus rests on its clinical pipeline, particularly the development of SER-155. This orally administered biotherapeutic aims to prevent bacterial bloodstream infections in patients who have undergone stem cell transplants. Recent efforts to consolidate resources and adjust workforce allocation are specifically targeted to concentrate capacity on this high-priority program, along with other candidates, SER-603 and SER-147.

Upcoming Milestones for Shareholders

Investors can expect several administrative deadlines in the coming weeks. The window for shareholder proposals is currently open.